

Supplemental Figure 1: Graphical abstract.



**Supplemental Figure 2**: **Antibody and staining validation.** A) NK and T cell pellets for positive/ negative validation. B) Antibody dilutions on tonsil tissue. Green boxes indicate the concentration used for multiplex. C) Monoplex/Multiplex staining on HGSC optimization tissue. Image captured on the Mantra (Akoya Biosciences) at a magnification of 20x.

Tissue	PanCk Pathology Views	InForm Segmentation	Pathologist Segmentation	DAPI Pathology Views	InForm Cell Segmentation	InForm Count	Pathologist Count	InForms accurarcy in %
1 (C56)						119	175	68%
2 (F76)						130	147	88%
3 (E171)			Prefe			143	156	92%
4 (C12)						135	142	95%
5 (C221)						143	190	75%
6 (C196)						105	113	93%
7 (C104)						116	105	110%
8 (C230)				ALCO Y		71	60	118%
9 (C162)	228 s a se	Part - in	215 · · · ·			70	67	104%
10 (E272)				A. M. M.		83	73	113%

**Supplemental Figure 3: Representative digital and manual pathology segmentation and scoring.** Tissue segmentation was assigned to each core after training of the machine learning algorithm in InForm digital pathology software. Pathologist TA segmented the same cores, blinded to the InForm outcomes. Pathology views, InForm segmentation and the pathologist's segmentation are shown. Cell segmentation was trained to recognize individual cell nuclei and InForm or pathologist TA independently counted individual cells. The range and variation between counts is shown.



Supplemental Figure 4: Pearson correlation between cell density quantified in duplicate cores (Core A vs. Core B) isolated from the same patient tumourss.



**Supplementary Figure 5. Gating strategy.** 

Characteristics	Category	$N(\theta_{\alpha})$		
Dationta	Number of nationts represented in	1 1/(70)		
ratients	TMA	1,145 (10076)		
	IMA			
Age	Median (range)	62 (26-91)		
Diagnosis Year	1992-1995	14 (1.2%)		
	1996-2000	104 (9.1%)		
	2001-2005	302 (26.4%)		
	2006-2010	482 (42.1%)		
	2011-2012	169 (14.8%)		
	2013-2014	49 (4.3%)		
Tumour Grade	Grade 2	132 (11.5%)		
	Grade 3	850 (74.2%)		
FIGO Tumour	Ι	76 (6.6%)		
Stage	II	120 (10.5%)		
	III	789 (68.9%)		
	IV	107 (9.3%)		
BRCA Status	BRCA WT	330 (28.8%)		
	BRCA1 mutated	52 (4.5%)		
	BRCA2 mutated	19 (1.7%)		
	BRCA1/2 mutated	2 (0.2%)		
Debulking Status	No residual disease	277 (24.2%)		
	Residual disease	584 (51%)		

## Supplementary Table 1: Aggregate clinical data.

Marker	Round	Species	Clone #	Blocking	AR	Polymer	Ab Dilution	Fluorophore	OPAL Dilution
CD3	1	Mouse	LN10	OPAL	9	Ms + Rb HRP	1/50	650	1/100
CD16a	2	Rabbit	SP175	OPAL	9	Ms + Rb HRP	1/50	520	1/100
CD94	3	Rabbit	ERP21003	OPAL	9	Ms + Rb HRP	1/100	570	1/100
CD68	4	Mouse	PGM1	OPAL	9	Ms + Rb HRP	1/100	620	1/100
panCk	5	Mouse	AE1/AE3	OPAL	9	Ms + Rb HRP	1/50	480	1/50
DAPI	6								

Supplementary Table 2: OPAL TSA-based multiplex immunofluorescence panel.

Antibody Target	Clone	Source
CD3	UCHT-1	BD Biosciences, San Jose, CA
CD56	NCAM16.2	BD Biosciences, San Jose, CA
CD16	3G8	BD Biosciences, San Jose, CA
CD39	Tü66	BD Biosciences, San Jose, CA
CD73	AD2	BD Biosciences, San Jose, CA
TIM-3	7D3	Biolegend, San Diego, CA
NKG2A	REA110	Miltenyi Biotec, San Diego, CA
NKG2D	1D11	BD Biosciences, San Jose, CA
NKp46	9-E2	BD Biosciences, San Jose, CA
CD107a	H4A3	BD Biosciences, San Jose, CA

Supplementary Table 3: Flow Cytometry antibody panel.